Explore Pharmaceutical Products Developed by Therapeutic Vision, Inc.
For more than 17 years, our team at Omaha, Nebraska has been developing a variety of pharmaceutical products for eye care. Learn more about the studies done featuring our medications.
Kinostat® Could Be Man's Best Friend
Professor Peter F. Kador has developed topical Kinostat® to ameliorate the development and progression of cataracts in dogs with diabetes mellitus.
Topical Kinostat® Ameliorates the Clinical Development and Progression of Cataracts in Dogs With Diabetes Mellitus
This study was conducted to determine whether topical administration of the aldose reductase inhibitor Kinostat can ameliorate the onset or progression of cataracts in dogs with naturally occurring diabetes mellitus (DM).
Aldose Reductase, Ocular Diabetic Complications, and the Development of Topical Kinostat®
Diabetes mellitus (DM) is a major health problem with devastating effects on ocular health in both industrialized and developing countries. The control of hyperglycemia is critical to minimizing the impact of DM on ocular tissues.
Effects Of Topical Administration Of An Aldose Reductase Inhibitor On Cataract Formation In Dogs Fed A Diet High In Galactose
This study shows that the topical application of Kinostat® appears to arrest or reverse the development of experimentally induced sugar cataracts in dogs. This suggests that intervention with Kinostat® at the early stages of sugar cataract formation may be beneficial in maintaining or improving functional vision in dogs developing sugar cataracts.
Topical Nutraceutical Optixcare EH Ameliorates
A study based on the hypothesis that oral nutraceuticals do not adequately reach all ocular tissues in the anterior segment.